Purpose
Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced
breast cancer. While
pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard
therapy options seem to be exhausted up to now after the treatment of patients with these two
therapy options. Therefore, it is important to have data that describes the
therapy situation and prognosis after T-DM1 treatment. Methods The PRAEGNANT metastatic
breast cancer registry (NCT02338167) is a prospective registry for
breast cancer patients with a focus on molecular
biomarkers. Patients of all
therapy lines with any kind of treatment are eligible. Collected data comprises
therapies, adverse events, quality of life and other patient reported outcomes. Here we report on the patient characteristics and descriptive prognostic data for HER2-positive patients who have completed a treatment with T-DM1.
Therapy patterns after T-DM1 and progression-free survival are reported as well as overall survival. Results A total of 85 patients were identified for the study who were prospectively observed during
therapy after the termination of T-DM1. The main reason for T-DM1 termination was progress. Following T-DM1,
lapatinib,
trastuzumab and
chemotherapy were the main
therapy choices. Median progression-free survival was 4.8 months (95% CI: 3.2 - 6.3) and median overall survival was 18.4 months (95% CI: 15.5 - 21.3). Conclusions
Therapy options after T-DM1 in a real-world setting seem to exhibit a relevant clinical efficacy, supporting the concept of continuous anti-HER2 treatments in the advanced
therapy setting for
breast cancer patients. Novel
therapies are needed to improve the rather short median progression-free survival.